Neovacs SA  

(Public, EPA:ALNEV)   Watch this stock  
Find more results for ALNEV
+0.010 (1.27%)
Nov 27 - Close
EPA real-time data - Disclaimer
Currency in EUR
Range 0.77 - 0.82
52 week 0.66 - 3.82
Open 0.80
Vol / Avg. 0.00/391,835.00
Mkt cap 25.65M
P/E     -
Div/yield     -
EPS -0.33
Shares 22.92M
Beta     -
Inst. own     -
Nov 3, 2015
Neovacs SA at �EBD BIO Europe- Fall
Oct 7, 2015
Neovacs SA at CF&B Communication European Large & Midcap Event

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -4198.85% -5297.47%
Operating margin -5967.65% -6811.54%
EBITD margin - -6771.87%
Return on average assets -94.19% -87.05%
Return on average equity -633.23% -442.02%
Employees 17 -
CDP Score - -


3-5, Impasse Reille, Paris 14
PARIS, 75014
+33-1-53109300 (Phone)
+33-1-53109303 (Fax)

Website links


Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States.

Officers and directors

Jean-Jacques Bertrand Chairman of the Board of Directors
Age: 57
Miguel Sieler Chief Executive Officer
Geraldine Grouard-Vogel Chief Scientific Officer
Nathalie Thomas-Pujol Head of Regulatory Affairs
Therese Croughs Chief Medical Officer
Michel Finance Director
Philippe Pouletty Director, Representative of Truffle Capital
Age: 55
Daniel Zagury Director
Edmond Alphandery Independent Director
Age: 71
Arlene M. Morris Independent Director
Age: 63